請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63290
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林淑文 | |
dc.contributor.author | Ping-Hui Lin | en |
dc.contributor.author | 林品慧 | zh_TW |
dc.date.accessioned | 2021-06-16T16:33:01Z | - |
dc.date.available | 2018-03-04 | |
dc.date.copyright | 2013-03-04 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-11-30 | |
dc.identifier.citation | 1. Yee-Chun Chen, Sheng-Fong Lin, Chieh-Ju Liu, Donald Dah-Shyong Jiang, Pan-Chy Yang, Chang S-C. Risk factors for ICU mortality in critically ill patients. J Formos Med Assoc 2001;100:656-61.
2. Vincent J-L, Rello J, Marshall J, et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009;302:2323-9. 3. Gaynes R, Jonathan R. Edwards, System tNNIS. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clin Infect Dis 2005;41:848-54. 4. Jean S-S, Hsueh P-R, Lee W-S. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009 33:266-71. 5. 李聰明, 蘇秋霞, 周偉惠. 2009年台灣院內感染監視系統分析報告. 感染雜誌 2011;21:195-201. 6. 吳宜真. 綠膿桿菌菌血症之預後因子及感染多重抗藥性綠膿桿菌菌血症之危險因子分析:著重於抗生素治療之影響: 臺灣大學; 2008. 7. Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004;125:607-16. 8. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46:862-7. 9. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement 2012. 10. European Committee on Antimicrobial Susceptibility Testing 2012. 11. Hung MN, Hsueh PR, Chang HT, et al. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data. Int J Antimicrob Agents 2007;29:145-52. 12. Hayashi Y, Roberts JA, David L Paterson, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism & Toxicology 2010;6:1017-31. 13. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5:365-83. 14. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010. 15. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob Agents Chemother 1996;40:829-34. 16. Micromedex DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically 17. 行政院衛生署中央健保局 (Accessed 2012/8/14, 2012, at http://www.nhi.gov.tw/query/query1.aspx?Name=piperacillin.) 18. Product Information: Tazocin® IV injection, piperacillin and tazobactam IV injection. Pfizer Pharmaceuticals Inc., 2001. 19. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 2008;12 Suppl 4:S2. 20. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006;26:1320-2. 21. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin 2011;27:77-93. 22. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-24. 23. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In Vitro Pharmacodynamics of Ceftazidime against Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. Antimicrob Agents Chemother 1997;41:2053-6. 24. Tam VH. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002;50:425-8. 25. Williamson R, Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur J Biochem 1985;151:475-83. 26. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nature reviews Microbiology 2004;2:289-300. 27. Craig WA. Pharmacokinetic Pharmacodynamic Parameters Rationale for Antibacterial Dosing of Mice and Men. Clinical Infectious Diseases 1998;26:1-10. 28. Aryun Kim, Christina A. Sutherland, Joseph L. Kuti, Nicolau DP. Optimal Dosing of Piperacillin-Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion? Pharmacotherapy 2007;27:1490-7. 29. Turnidge JD. The Pharmacodynamics of β-Lactams. Clin Infect Dis 1998;27:10-22. 30. Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993;31 Suppl A:39-60. 31. Johnson CA, Halstenson CE, Kelloway JS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992;51:32-41. 32. P Bourget, A Lesne-Hulin, R Le Reveillé, H Le Bever, Carsin H. Clinical Pharmacokinetics of Piperacillin-Tazobactam Combination in Patients with Major Burns and Signs of Infection. Antimicrob Agents Chemother 1996;40:139-45. 33. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2009;34:429-33. 34. Oh KH, Kim C, Lee H, et al. Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration. Antimicrob Agents Chemother 2009;53:3266-8. 35. Brogard JM, Jehl F, Blickle JF, Dorner M, Arnaud JP, Monteil H. Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. International journal of clinical pharmacology, therapy, and toxicology 1990;28:462-70. 36. Curtis A. Johnson, Charles E. Halstenson, Judy S. Kelloway, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992;51:32-41. 37. Wise R, Logan M, Cooper M, Andrews JM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991;35:1081-4. 38. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010;14:R126. 39. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004;30:2145-56. 40. van der Poll T. Immunotherapy of sepsis. The Lancet infectious diseases 2001;1:165-74. 41. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51; quiz 59. 42. Conil JM, Georges B, Lavit M, et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007;64:27-35. 43. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 2010;99:1107-22. 44. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-7. 45. Occhiointi DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and Pharmacodynamics of Two Multiple-Dose Piperacillin-Tazobactam Regimens. Antimicrob Agents Chemother 1997;41:2511-7. 46. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-95. 47. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010;35:156-63. 48. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-7. 49. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009;43:1747-54. 50. Lodise TP, Lomaestro B, George LD. Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection Clinical Implications of an Extended- Infusion. Clin Infect Dis 2007;44:357-63. 51. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009;64:236-40. 52. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7. 53. Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61. 54. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-8. 55. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical Efficacy and Pharmacoeconomics of a Continuous infusion piperacillin tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83. 56. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. 57. Huang PC, You SL, Lin YM, Chu CL. Body weight of Chinese adults by sex, age and body height and criterion of obesity based on body mass index. J Chin Nutr Soc 1992;17:157-72. 58. Di Giovamberardino G, Ferrannini M, Testore GP, Federici G, Pastore A. High performance liquid chromatographic determination of plasma free and total tazobactam and piperacillin. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:86-8. 59. DiPiro JT. Concepts in clinical pharmacokinetics. Bethesda, MD: American Society of Health-System Pharmacists; 2005. 60. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. 61. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:A0828. 62. 吳寬墩, 陳鴻鈞. 建立國人腎絲球濾過率公式及慢性腎臟病的分期標準. 行政院衛生署新聞 2011. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63290 | - |
dc.description.abstract | 背景:
感染症是常導致病人住院或死亡的重要原因,尤其是革蘭氏陰性菌造成的感染致死率高。隨著菌株抗藥性日益增加,若將現有之抗生素依照其藥動、藥效學特性最佳化,才能成功地治療感染症。Piperacillin/tazobactam臨床上常用於治療革蘭氏陰性菌的感染,其藥動學及藥效學性質為「時間依賴型」(time-dependent),自由型(free form)抗生素的血中濃度若能維持在病原菌的最小抑菌濃度(minimal inhibitory concentration,MIC)以上愈久,相對於每次給藥間隔(dosing interval)的比例愈高(%fT>MIC),治療感染症的效果愈好。國際上有許多以藥動學及藥效學模式模擬的研究,但完全以重症病人為研究對象的文獻相當少見。 研究目的: 分析在重症病人延長給予piperacillin/tazobactam輸注時間對藥動、藥效學參數的影響及與一般病人之差異。比較在重症病人延長輸注時間及傳統給藥方式給予piperacillin/ tazobactam後的piperacillin之% fT>MIC是否有顯著差異,並模擬不同給藥方式的藥效學指標達成率(probability of target attainment,PTA)。本研究同時評估重症病人延長輸注時間給予piperacillin/tazobactam時的臨床療效及安全性。 研究方法: 本研究為一前瞻性、開放性、隨機分配之藥品動態學及藥效學之臨床研究,自2012年2月20日至2012年7月31日在臺大醫院內科及呼吸加護病房進行收案。收納條件為大於18歲、住在加護病房、肌酐酸廓清率大於20 mL/min、且預期使用piperacillin/tazobactam藥品大於3天之病人。給藥劑量依照醫師根據病人感染部位及腎功能給予,病人簽署受試者同意書後,隨機分派至藥品靜脈輸注時間4小時(EI)或1小時(II)的組別,並皆於達到穩定濃度後的一個給藥區間抽取6個不同時間的血液檢體,利用高效能液相層析儀(high-performance liquid chromatography,HPLC)分析血中濃度,並利用WinNonlin之non-compartment model分析藥動學參數及藥效學結果,以蒙地卡羅模擬進行PTA的分析。 研究結果: 本研究共收案24人,兩組各12位病人,平均年齡為76.91 ± 10.53歲,男女比例14:10,平均體重53.78 ± 10.16公斤。在使用piperacillin/tazobactam時的APACHE II 分數中位數為26(15-32),多數病人以肺部感染為主,占83.3%。 共收集144筆血中濃度資料,使用3克的piperacillin最高及最低濃度平均分別為178.77 ± 63.64 mg/L及60.73 ± 51.06 mg/L;而4克則為205.43 ± 98.80 mg/L及56.83 ± 50.24 mg/L。EI組及II組的藥動學參數皆沒有差異,其piperacillin的排除速率常數分別為0.3 hr-1及0.43 hr-1、半衰期為2.34 hr及1.61 hr、廓清率為4.6 L/hr及6.16 L/hr,而擬似分佈體積為0.32 L/kg及0.30 L/kg。相較於健康人或一般住院病人,重症病人的Vd有偏大、CL偏低、t1/2偏長的趨勢。 在MIC較低時,兩組的% fT>MIC皆將近100%;隨MIC增高,EI組的% fT>MIC有較大的趨勢。當MIC為32 mg/L時,EI組平均有95.47%的時間達到% fT>MIC,而II組平均則有84.77%的時間,p值為0.0282。若MIC更高為64 mg/L或128 mg/L時,雖然EI組平均仍有較高的比例達到% fT>MIC,但都沒有統計顯著差異。蒙地卡羅模擬結果顯示,若給予相同劑量及給藥頻次,則EI組的PTA較高。在MIC為16 或32 mg/L時,4 g Q8H輸注4小時的PTA均高達90%以上,高於輸注1小時的86.96%與65.67%。 兩組病人在14天內死亡率或住院天數沒有顯著差異,也沒有病人發生癲癇或骨髓抑制等與劑量相關的副作用。 結論: 在重症病人使用piperacillin/tazobactam靜脈輸注4小時及1小時,除了血中濃度以外,其他藥動參數沒有差異。相較於健康人或一般住院病人,piperacillin在重症病人有Vd偏大、t1/2偏長的趨勢。EI組血中濃度變化不如II組大,因此病人的實際% fT>MIC在EI組略高,但兩組在MIC低時皆將近100%時間可達到目標,在MIC較高時差異較大,惟並不顯著。蒙地卡羅模擬看到相同趨勢,在MIC較高時,延長靜脈輸注推估可以最適化藥動學及藥效學結果。 在本針對重症病人的研究中,並未如文獻看到延長靜脈輸注比起30分鐘輸注在藥效學的顯著益處,但有觀察到輸注四小時之PTA比輸注一小時有較好的趨勢。儘管在MIC≤32 mg/L時,一個小時的輸注就有理想藥效,但由於在一開始經驗性給予piperacillin/tazobactam時並不知菌株的MIC,因此若病人疾病嚴重程度高或免疫較差,仍希望% fT>MIC越高越好,而使用較長的靜脈輸注時間可有效達到此目的。考量劑量、可行性等其他臨床因素,本研究建議重症病人經驗性可給予4 g Q8H且延長輸注時間至4小時;若有菌株培養結果,且菌株感受性為sensitive時可考慮使用3 g Q8H輸注4小時,以達到較佳的藥動/藥效學參數,而延長靜脈輸注時間給予piperacillin/tazobactam對於臨床療效的影響則需要未來更多的研究證明。 | zh_TW |
dc.description.abstract | Background:
With the increasing resistance of Gram-negative bacteria which is the major cause for morbidity and mortality, optimizing the existing antibiotics according to their pharmacokinetic (PK) and pharmacodynamic (PD) characteristics may optimize the treatment of infectious diseases. Piperacillin/tazobactam (pip/tazo) is one of the β-lactam antibiotics often used in the treatment of infections caused by Gram-negative bacteria. Pip/tazo exhibits“time-dependent”bactericidal activities. The killing effect is proportional to the time of the free form of pip/tazo serum concentration remaining above the minimal inhibitory concentration (MIC) relative to one dosing interval. When the goal of % fT>MIC of pip/tazo exceed 50% of the dosing interval, better treatment outcomes are reported. Many publications have demonstrated PK and PD models via simulation while studies in critically ill patients were few. Purpose: The purpose of this study was to evaluate PK and PD parameters in critically ill patients with extended infusion of pip/tazo. We also compared the % fT>MIC of pip/tazo in critically ill patients with extended infusion and traditional administration in ICU (1 hr-infusion). Furthermore, the probability of target (> 50% fT>MIC) attainment (PTA) in different dosing regimens was estimated via Monte Carlo simulation. The efficacy and safety of extended infusion in intensive care patients was also included in this study. Methods: This was a prospective, open-label, randomized clinical PK study in critically ill patients in medical and respiratory intensive care units (ICUs) at National Taiwan University Hospital from 20th February, 2012 to 31st July, 2012. Patients received pip/tazo were eligible if they were ≥18 years old, staying in an ICU, with CLcr ≥ 20 mL/min and expected on pip/tazo for ≥ 3 days. Dosing regimen was determined by physician according to patient’s infection site and renal function. Patients were randomized to either extended infusion (EI) group or intermittent infusion (II) control group after signing the informed consent. Six blood samples at different time points were collected in one dosing interval at steady state. Non-compartmental model in WinNonlin was used in analyzing PK and PD parameters, and Monte Carlo simulation was conducted for PTA. Results: Twelve patients were allocated to each group. Their average age was 76.91 ± 10.53 years old, female accounted for 41.7% (10/24), and an average weight was 53.78 ± 10.16 kilograms. Median of APACHE II score was 26 (15-32) when pip/tazo was prescribed, and 83.3% was lung infections. A total of 144 serum samples were collected. The average piperacillin Cmax and Cmin of 3 g (4g) was 178.77 ± 63.64 mg/L (205.43 ± 98.80 mg/L) and 60.73 ± 51.06 mg/L (56.83 ± 50.24 mg/L), respectively. The piperacillin elimination rate constant (k), half-life (t1/2), clearance (CL) and volume of distribution (Vd) of EI and II group were 0.3 hr-1 vs. 0.43 hr-1, 2.34 hr vs. 1.61 hr, 4.6 L/hr vs. 6.16 L/hr, 0.32 L/kg vs. 0.30 L/kg, respectively, and there was no statistically significant difference between two groups. These parameters had tendency to be larger in Vd and t1/2, and smaller in CL. The % fT>MIC were approaching to 100% in both groups, and became larger in EI group at higher MIC. When MIC was 32 mg/L, EI group had an average of 95.47% of the time above MIC compares to 84.77% in II group (p = 0.0282). There was no statistically significance between two groups though higher proportion of % fT>MIC in EI group when MIC ≥ 64 mg/L. Results from Monte Carlo simulation showed higher PTA in EI group under the same dosing regimen. The PTAs exceeded 90% for EI of 4 g Q8H compared with 86.96% and 65.67% for II of the same doing regimen at an MIC of 16 or 32 mg/L, respectively. There were no significant differences regarding the 14-day mortality, hospital length of stay, and dose-dependent side effects such as seizure or bone marrow suppression between two groups. Conclusion: Regarding to the PK parameters such as k, t1/2, CL and Vd, there were no statistically differences between EI and II group in critically ill patients treated with pip/tazo. Vd and t1/2 were larger, and CL was smaller. Serum concentrations fluctuated less during extending infusion, and this strategy was more likely to keep the target % fT>MIC. Although there were no significant differences in PD benefits in EI group vs. II group (1 hour) in this study compared to previous publications in which 30 min-infusion was administered in the II group.A 4-hr extended infusion regimen demonstrated a trend of better % fT>MIC and PTA at a higher MIC compared to 1-hr infusion. Therefore, extended infusion regimen may achieve a better PK-PD profile against pathogens with higher MIC when piperacillin/tazobactam was given as empirical treatment. Piperacillin/tazobactam 4 g Q8H with 4-hr IV infusion should be encouraged as empirical treatment for optimal PK-PD parameters considering daily dose, feasibility, and other clinical aspects. 3 g Q8H with 4-hr IV infusion can be considered when culture results with sensitive susceptibility are revealed. Further studies are needed for the impact of prolonged infusion on the treatment outcomes. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:33:01Z (GMT). No. of bitstreams: 1 ntu-101-R99451002-1.pdf: 1502233 bytes, checksum: e38b80e7de22946ff6534407e2d91029 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 目錄....................................................I
圖目錄..................................................IV 表目錄..................................................V 中文摘要................................................VII Abstract................................................X 縮寫表..................................................XIII 第1章 前言..............................................1 第2章 文獻探討..........................................2 2.1 革蘭氏陰性菌造成之院內感染........................2 2.2 Piperacillin/tazobactam簡介.......................4 2.2.1 藥理機轉......................................4 2.2.2 藥效學(pharmacodynamics, PD)特性............6 2.2.3 藥品動態學(pharmacokinetics, PK)特性........7 2.3 重症病人之藥品動態學的改變........................9 2.3.1 擬似分佈體積(volume of distribution,Vd......9 2.3.2 半衰期(half-life,t1/2).....................10 2.3.3 廓清率(clearance,CL).......................10 2.3.4 蛋白質結合率(protein binding)...............10 2.4 延長靜脈輸注(extended infusion)與傳統給藥(間歇性給 藥,intermittent infusion)方式對於病人藥動學及藥效學 的影響............................................11 2.5 延長靜脈輸注與傳統給藥方式用於治療感染病人臨床療效研究 之比較............................................14 第3章 研究目的..........................................17 第4章 研究方法..........................................18 4.1 研究架構..........................................18 4.2 病人的納入條件(inclusion criteria)及排除條件 (exclusion criteria).............................19 4.3 Piperacillin/tazobactam的給予方式.................20 4.4 試驗設計..........................................22 4.5 相關資料收集 ......................................23 4.5.1 受試者基本資料................................23 4.5.2 受試者基本檢驗值..............................23 4.5.3 抗生素使用情形................................23 4.5.4 其他..........................................23 4.6 濃度測定方法 ......................................23 4.6.1 血漿檢體前處理................................23 4.6.2 HPLC分析條件..................................24 4.6.3 分析方法確效..................................24 4.7 藥品動態學研究....................................25 4.8 臨床療效及安全性評估..............................26 4.9 統計方法..........................................26 第5章 研究結果..........................................27 5.1 研究收案病人流程..................................27 5.2 病人基本資料 ......................................28 5.3 藥品動態學........................................35 5.4 藥效學結果........................................41 5.4.1 % fT>MIC ......................................41 5.4.2 蒙地卡羅模擬(Monte Carlo simulation)........49 5.5 臨床療效及安全性比較..............................51 第6章 討論..............................................52 6.1 病人族群..........................................52 6.2 病人藥品動態學分析................................53 6.3 病人藥效學分析....................................57 6.4 臨床療效及安全性分析..............................60 6.5 研究限制..........................................61 第7章 結論..............................................62 第8章 參考資料..........................................63 附錄....................................................68 個別病人之piperacillin/tazobactam濃度對時間作圖.......68 | |
dc.language.iso | zh-TW | |
dc.title | 延長piperacillin/tazobactam靜脈輸注時間在重症病人之藥動學及藥效學研究 | zh_TW |
dc.title | A pharmacokinetic and pharmacodynamic study of extended infusion of piperacillin/tazobactam in critically ill patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 沈麗娟 | |
dc.contributor.oralexamcommittee | 李啟明,盛望徽 | |
dc.subject.keyword | Piperacillin/tazobactam,重症病人,藥動學,藥效學,延長靜脈輸注時間, | zh_TW |
dc.subject.keyword | Piperacillin/tazobactam,critically ill,pharmacokinetics,pharmacodynamics,extended infusion, | en |
dc.relation.page | 76 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-12-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。